http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 16:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+DOMINION+ENERGY%2C+INC/26617805.html si-local-file:///var/storage/secattach/20260608/26617805.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+DOMINION+ENERGY%2C+INC/26617805.html Mon, 08 Jun 2026 16:30:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+DOMINION+ENERGY%2C+INC/26617805.html si-local-file:///var/storage/secattach/20260608/26617805.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+DOMINION+ENERGY%2C+INC/26617805.html Mon, 08 Jun 2026 16:30:00 -0400 D O.00063161 http://www.streetinsider.com/Press+Releases/Dominion+Energy+prepares+year-round+for+hurricane+season+and+encourages+customers+to+prepare+as+well/26615481.html <ul class="bwlistdisc"> <li> <i>Year-round preparation includes trimming trees near power lines, burying lines in outage-prone areas, and replacing older utility poles</i> </li> <li> <i>Customers are encouraged to prepare by downloading the Dominion Energy mobile app, charging devices before storms and other helpful tips</i> </li> </ul> <p> RICHMOND, Va.--(BUSINESS WIRE)-- As hurricane season begins, Dominion Energy Virginia continues its year-round storm preparation to strengthen the grid, reduce power outages and shorten restoration times. </p><p> The company’s storm preparation work includes regularly trimming trees near power lines, burying lines in the most outage-prone areas, and replacing older utility poles to better withstand major storms. Fallen trees and limbs are the http://www.streetinsider.com/Press+Releases/Dominion+Energy+prepares+year-round+for+hurricane+season+and+encourages+customers+to+prepare+as+well/26615481.html Mon, 08 Jun 2026 10:00:00 -0400 D O.00063161 http://www.streetinsider.com/Press+Releases/Dominion+Energy+prepares+year-round+for+hurricane+season+and+encourages+customers+to+prepare+as+well/26615481.html <ul class="bwlistdisc"> <li> <i>Year-round preparation includes trimming trees near power lines, burying lines in outage-prone areas, and replacing older utility poles</i> </li> <li> <i>Customers are encouraged to prepare by downloading the Dominion Energy mobile app, charging devices before storms and other helpful tips</i> </li> </ul> <p> RICHMOND, Va.--(BUSINESS WIRE)-- As hurricane season begins, Dominion Energy Virginia continues its year-round storm preparation to strengthen the grid, reduce power outages and shorten restoration times. </p><p> The company’s storm preparation work includes regularly trimming trees near power lines, burying lines in the most outage-prone areas, and replacing older utility poles to better withstand major storms. Fallen trees and limbs are the http://www.streetinsider.com/Press+Releases/Dominion+Energy+prepares+year-round+for+hurricane+season+and+encourages+customers+to+prepare+as+well/26615481.html Mon, 08 Jun 2026 10:00:00 -0400 D O.00063161 http://www.streetinsider.com/Business+Wire/Dominion+Energy+prepares+year-round+for+hurricane+season+and+encourages+customers+to+prepare+as+well/26615481.html <ul class="bwlistdisc"> <li> <i>Year-round preparation includes trimming trees near power lines, burying lines in outage-prone areas, and replacing older utility poles</i> </li> <li> <i>Customers are encouraged to prepare by downloading the Dominion Energy mobile app, charging devices before storms and other helpful tips</i> </li> </ul> <p> RICHMOND, Va.--(BUSINESS WIRE)-- As hurricane season begins, Dominion Energy Virginia continues its year-round storm preparation to strengthen the grid, reduce power outages and shorten restoration times. </p><p> The company’s storm preparation work includes regularly trimming trees near power lines, burying lines in the most outage-prone areas, and replacing older utility poles to better withstand major storms. Fallen trees and limbs are the http://www.streetinsider.com/Business+Wire/Dominion+Energy+prepares+year-round+for+hurricane+season+and+encourages+customers+to+prepare+as+well/26615481.html Mon, 08 Jun 2026 10:00:00 -0400 D O.00063161 http://www.streetinsider.com/Business+Wire/Dominion+Energy+prepares+year-round+for+hurricane+season+and+encourages+customers+to+prepare+as+well/26615481.html <ul class="bwlistdisc"> <li> <i>Year-round preparation includes trimming trees near power lines, burying lines in outage-prone areas, and replacing older utility poles</i> </li> <li> <i>Customers are encouraged to prepare by downloading the Dominion Energy mobile app, charging devices before storms and other helpful tips</i> </li> </ul> <p> RICHMOND, Va.--(BUSINESS WIRE)-- As hurricane season begins, Dominion Energy Virginia continues its year-round storm preparation to strengthen the grid, reduce power outages and shorten restoration times. </p><p> The company’s storm preparation work includes regularly trimming trees near power lines, burying lines in the most outage-prone areas, and replacing older utility poles to better withstand major storms. Fallen trees and limbs are the http://www.streetinsider.com/Business+Wire/Dominion+Energy+prepares+year-round+for+hurricane+season+and+encourages+customers+to+prepare+as+well/26615481.html Mon, 08 Jun 2026 10:00:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26614708.html si-local-file:///var/storage/secattach/20260608/26614708.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26614708.html Mon, 08 Jun 2026 08:28:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26614708.html si-local-file:///var/storage/secattach/20260608/26614708.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26614708.html Mon, 08 Jun 2026 08:28:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++425++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+NEXTERA+ENERGY+INC/26611612.html si-local-file:///var/storage/secattach/20260605/26611612.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+NEXTERA+ENERGY+INC/26611612.html Fri, 05 Jun 2026 16:32:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++425++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+NEXTERA+ENERGY+INC/26611612.html si-local-file:///var/storage/secattach/20260605/26611612.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+NEXTERA+ENERGY+INC/26611612.html Fri, 05 Jun 2026 16:32:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DOMINION+ENERGY%2C+INC++++++For%3A+Jun+03/26609041.html si-local-file:///var/storage/secattach/20260605/26609041.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DOMINION+ENERGY%2C+INC++++++For%3A+Jun+03/26609041.html Fri, 05 Jun 2026 09:26:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DOMINION+ENERGY%2C+INC++++++For%3A+Jun+03/26609041.html si-local-file:///var/storage/secattach/20260605/26609041.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DOMINION+ENERGY%2C+INC++++++For%3A+Jun+03/26609041.html Fri, 05 Jun 2026 09:26:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++424B2++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26606376.html si-local-file:///var/storage/secattach/20260604/26606376.html http://www.streetinsider.com/SEC+Filings/Form++424B2++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26606376.html Thu, 04 Jun 2026 16:41:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++424B2++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26606376.html si-local-file:///var/storage/secattach/20260604/26606376.html http://www.streetinsider.com/SEC+Filings/Form++424B2++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26606376.html Thu, 04 Jun 2026 16:41:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+DOMINION+ENERGY%2C+INC/26599412.html si-local-file:///var/storage/secattach/20260603/26599412.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+DOMINION+ENERGY%2C+INC/26599412.html Wed, 03 Jun 2026 16:30:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+DOMINION+ENERGY%2C+INC/26599412.html si-local-file:///var/storage/secattach/20260603/26599412.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++DOMINION+ENERGY%2C+INC+++++++++++++++++++Filed+by%3A+DOMINION+ENERGY%2C+INC/26599412.html Wed, 03 Jun 2026 16:30:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26596072.html si-local-file:///var/storage/secattach/20260603/26596072.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26596072.html Wed, 03 Jun 2026 08:38:00 -0400 D O.00063161 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26596072.html si-local-file:///var/storage/secattach/20260603/26596072.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++DOMINION+ENERGY%2C+INC+++++++++++++++++/26596072.html Wed, 03 Jun 2026 08:38:00 -0400 D O.00063161 http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV. </p><p> OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026. http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html Tue, 02 Jun 2026 08:00:00 -0400 01801 A.06353047 D O.20403755 R http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV. </p><p> OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026. http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html Tue, 02 Jun 2026 08:00:00 -0400 01801 A.06353047 D O.20403755 R http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV. </p><p> OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026. http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html Tue, 02 Jun 2026 08:00:00 -0400 01801 A.06353047 D O.20403755 R http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV. </p><p> OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026. http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html Tue, 02 Jun 2026 08:00:00 -0400 01801 A.06353047 D O.20403755 R http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV. </p><p> OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026. http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html Tue, 02 Jun 2026 08:00:00 -0400 01801 A.06353047 D O.20403755 R http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV. </p><p> OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026. http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html Tue, 02 Jun 2026 08:00:00 -0400 01801 A.06353047 D O.20403755 R http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html <p> AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from June 12-13 in Las Vegas, NV. </p><p> OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody expected to enter Phase 3 clinical development for DME and wAMD in the second half of 2026. http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+20-week+Data+from+Randomized+Head-to-Head+Study+of+OLN324+Compared+to+Faricimab+%28Vabysmo%C2%AE%29+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+/26587659.html Tue, 02 Jun 2026 08:00:00 -0400 01801 A.06353047 D O.20403755 R